Investor Relations
Corporate Profile
Monte Rosa Therapeutics is a clinical stage biotechnology company developing novel molecular glue degrader (MGD) medicines for patients living with serious diseases such as oncology, autoimmune and inflammatory diseases. MGDs are small molecule protein degraders designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) platform enables it to rapidly identify protein targets and design highly selective degraders by combining diverse libraries of proprietary MGDs with in-house proteomics, structural biology, AI/machine learning, and computational chemistry capabilities. Monte Rosa is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.
Recent Updates
8.28.2024
press release
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
presentations
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader
download
corporate presentation
Monte Rosa Corporate Presentation – August 2024
download
6th Annual Inflammasome Summit – Exploring Novel Modalities: Disabling the NLRP3 Inflammasome with a NEK7 Molecular Glue Degrader
view pdf
Trends in Immunology - VAV1 as a Putative Therapeutic Target in Autoimmune and Chronic Inflammatory Diseases
view pdf
EULAR 2024 – MRT-6160, a VAV1-Directed Molecular Glue Degrader, Reduces Joint Inflammation and Autoantibody Production in a Collagen-Induced Arthritis Autoimmune Disease Model
view pdf